Review Article
The Impact of Mass Drug Administration on Lymphatic Filariasis
Table 4
Percentage antigenic prevalence reduction at mid-term and pre-TAS compared to baseline prevalence in LF mass drug administration.
| Reference, country | Baseline antigen prevalence (N) | LF antigen prevalence (N); % antigen PR | Mid-term | Pre-TAS |
| [14], Mali | 21.42 (1139) | — | 0 (760); 100.00 | [15], American Samoa | 16.00 (3018) | — | 2.29 (1881); 85.69 | [16], Egypt | 19.00 (1000) | — | 2.70 (1000); 85.79 | [20], Egypt | 32.61 (1877) | — | 7.88 (1828); 75.84 | [19], Nigeria | 21.61 (2439) | — | 7.38 (1720); 65.85 | [23], Tanzania | 23.65 (888) | 10.60 (953); 51.18 | — | [26], Indonesia | 6.51 (722) | 1.15 (871); 82.33 | — | [27], Papua New Guinea | 47.49 (558) | 17.13 (543); 63.93 | — |
|
|
LF: lymphatic filariasis; N: sample size; pre-TAS, pretransmission assessment survey; % antigen PR, percentage antigen prevalence reduction compared to baseline antigen prevalence; —: no data available. |